Key Highlights

  • Gilead Sciences (Nasdaq: GILD) signed a $139.8m API Supply pact with Yuhan Corporation, its fourth deal since 2024
  • The five-year contract brings Yuhan’s total Gilead-related orders to $270m, accelerating its contract development Manufacturing expansion
  • South Korea’s pharma exports hit a record $16.8bn in 2025—APIs now account for more than 40% of the value
  • Analysts at Hanwha Securities project Yuhan’s API Revenue to grow 22% annually through 2028 on Gilead and other Western deals
  • Gilead’s HIV Franchise relies increasingly on Asian CDMOs; 30% of its API Volume now originates from Korea and India

Company Overview

Yuhan Corporation is South Korea’s oldest listed drugmaker, founded in 1926; it has pivoted from branded generics to high-Margin active pharmaceutical ingredients (APIs) and contract development and manufacturing organisation (CDMO) services. The Seoul-based group operates two dedicated API plants in Incheon and Daejeon, certified by the US FDA and the European Medicines Agency, and supplies roughly 40 generic and specialty APIs to 30 countries. At the end of March 2026, Yuhan reported a Market Capitalisation of ₩1.2trn ($900m) on the Korea Exchange, up 38% over the past year as investors bet on its export-led growth. The company’s stated ambition—“to become Asia’s fourth-largest CDMO by 2030”—reflects a broader Korean push to capture mid-stream manufacturing from Western pharma majors seeking supply-chain resilience.

Key Developments

On May 20th 2026 Yuhan Corporation announced a five-year supply agreement worth ₩210.2bn ($139.8m) with Gilead Sciences (NASDAQ: GILD) for antiretroviral APIs used in HIV treatments (Koreabiomed, May 20 2026). The deal follows a 2025 pact valued at $80.9m and two earlier smaller contracts, bringing cumulative Gilead orders to $270m, per company disclosures. Separately, Yuhan disclosed plans to invest ₩150bn through 2027 to expand fermentation and high-potent API capacity, citing “robust Demand from North American and European customers”. Regulatory filings show the Incheon Facility received US FDA pre-approval for tenofovir prodrug in March 2026, streamlining export clearance. The company also appointed former Samsung Biologics executive Lee Ji-hoon as head of CDMO strategy in February 2026 to accelerate Western market penetration.

Financial Analysis

Yuhan’s trailing-twelve-month API revenue reached ₩424bn ($320m) in Q1 2026, up 34% year-on-year (company IR, April 2026), driven by Gilead and European generics clients. Gross margins improved to 41% from 36% a year earlier as scale Economics kicked in; net profit rose 68% to ₩92bn, helped by a weaker Korean won and higher export ASPs. The latest Gilead contract—spread over five years—should add ₩160–170bn to annual top-line by 2028, according to analyst consensus compiled by Kiwoom Securities (April 2026). Yuhan ended March 2026 with net cash of ₩310bn ($230m) after paying down ₩80bn in Debt, giving it dry powder for the ₩150bn capacity expansion. At current prices the stock trades at 14× forward Earnings—cheaper than peers Celltrion (KRX: 068270, 18×) and Samsung Biologics (KRX: 207940, 26×)—yet offers the steepest earnings-per-share growth forecast (22% CAGR through 2028) among Korean CDMOs.

Industry & Sector Analysis

South Korea’s pharma API exports reached $16.8bn in 2025, up 18% year-on-year, according to the Korea Pharmaceutical Manufacturers Association, with APIs now comprising 42% of total drug exports—surpassing finished dosage forms for the first time. The sector benefits from Western “China+1” Diversification strategies and Korea’s 14 free-trade agreements, including the EU-Korea FTA which eliminated tariffs on 99% of pharma goods. Yuhan’s key listed peers—Samsung Biologics (KRX: 207940), Celltrion (KRX: 068270), ST Pharm (KRX: 084990)—have all signed multi-hundred-million-dollar CDMO deals in the past 12 months; Samsung alone landed a $2.5bn mRNA manufacturing pact with Moderna in 2025. However, Yuhan distinguishes itself by focusing on high-potency and controlled-substance APIs, a niche Western buyers prize for margin stability. Regulatory scrutiny is intensifying: the US FDA issued 18 warning letters to Korean API makers in 2025, up from six in 2022; yet Korea’s overall inspection pass rate remains above 90%, ahead of India’s 75%.

Risks & Catalysts

Near-term catalysts include the FDA’s tentative approval of Yuhan’s efavirenz API scheduled for Q3 2026, which could unlock $40m in additional annual sales to generic HIV formulators. Investors will watch Gilead’s HIV volume guidance—due in its Q2 2026 Earnings Call—for any signal that it will increase API off-shoring. On the risk side, geopolitical tensions over semiconductor and battery supply chains could escalate Korea’s trade frictions with China, the dominant buyer of Korean APIs. Margin pressure is another concern: raw-material prices for key starting materials (e.g., epichlorohydrin) rose 15% in Q1 2026, and the Korean won’s 5% appreciation since January erodes dollar-denominated revenues. Execution risk at the new Daejeon high-potent API facility—targeted for Q4 2026 start-up—looms large: any delay would forfeit $25m in annual margin uplift. Conversely, a successful FDA pre-approval for a new tenofovir prodrug analogue could add $120m in lifetime API orders from multiple innovators.